$100M financing to advance immuno-dermatology pipeline
Drug Discovery World
FEBRUARY 15, 2024
Alys believes that emerging indications such as atopic dermatitis, vitiligo, alopecia areata and chronic spontaneous urticaria, will see the next breakthroughs in dermatological advancements. Alys Pharmaceuticals has launched with an R&D pipeline enabled by multiple platform technologies and a $100 million financing by Medicxi.
Let's personalize your content